Elevar Receives FDA Complete Response Letter
FORT LEE, N.J., July 10, 2026 Elevar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has issued...
tyrosine kinase inhibitor
Advertisement
HUTCHMED Wins NMPA Approval for ORPATHYS® in Gastric Cancer
Hong Kong, Shanghai & Florham Park, N.J., July 2, 2026 HUTCHMED has achieved a major regulatory milestone after the...
Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has conditionally approved...
Bayer’s Sevabertinib Gets FDA Priority Review
BERLIN, Germany, May 18, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) granted Priority Review...
Cogent Biosciences Files NDA for Bezuclastinib in GIST
WALTHAM, Mass. and BOULDER, Colo., April 1, 2026 Cogent Biosciences, Inc. has announced the successful submission of a New...
Advertisements
Merck to Acquire Terns to Strengthen CML Pipeline
RAHWAY, New Jersey & FOSTER CITY, California, March 25, 2026 Merck & Co. has announced a definitive agreement to...
FDA Grants Breakthrough Therapy Status to Bezuclastinib in GIST
Waltham, Massachusetts & Boulder, Colorado, January 26, 2026 — Cogent Biosciences, Inc. announced that the U.S. Food and Drug...
Cogent NDA for Bezuclastinib Advances Under FDA RTOR
WALTHAM, Mass. & BOULDER, Colo., January 20, 2026 — Cogent Biosciences announced that the U.S. Food and Drug Administration...
Cogent Biosciences Secures $475M to Advance Precision Therapies
Dateline — WALTHAM, Mass. and BOULDER, Colo., November 11, 2025:Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company developing precision...
Advertisement
